R E Clark

2.6k total citations
24 papers, 821 citations indexed

About

R E Clark is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, R E Clark has authored 24 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Hematology, 6 papers in Genetics and 6 papers in Oncology. Recurrent topics in R E Clark's work include Chronic Myeloid Leukemia Treatments (13 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Eosinophilic Disorders and Syndromes (5 papers). R E Clark is often cited by papers focused on Chronic Myeloid Leukemia Treatments (13 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Eosinophilic Disorders and Syndromes (5 papers). R E Clark collaborates with scholars based in United Kingdom, Australia and Spain. R E Clark's co-authors include Athina Giannoudis, Munir Pirmohamed, L Wang, Steven Lane, Paula Williamson, Ian D. Kerr, Richard Callaghan, Claire Lucas, Robert J. Harris and Andrew Davies and has published in prestigious journals such as Blood, British Journal of Pharmacology and Clinical Pharmacology & Therapeutics.

In The Last Decade

R E Clark

24 papers receiving 795 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R E Clark United Kingdom 15 466 304 282 165 145 24 821
Gary Vanasse United States 15 299 0.6× 245 0.8× 138 0.5× 72 0.4× 223 1.5× 32 816
Sven‐Aage Killmann Denmark 17 432 0.9× 210 0.7× 127 0.5× 136 0.8× 284 2.0× 39 848
M. Schoester Netherlands 15 303 0.7× 74 0.2× 464 1.6× 88 0.5× 368 2.5× 23 752
Peter Ernst Saudi Arabia 16 347 0.7× 115 0.4× 204 0.7× 27 0.2× 288 2.0× 40 816
Tomasz Sacha Poland 14 466 1.0× 406 1.3× 134 0.5× 205 1.2× 175 1.2× 95 727
Marius Dohse Germany 9 180 0.4× 128 0.4× 497 1.8× 56 0.3× 230 1.6× 13 788
M Bouvier United States 11 427 0.9× 67 0.2× 175 0.6× 34 0.2× 78 0.5× 29 688
Yuri Yanishevski United States 13 220 0.5× 66 0.2× 183 0.6× 84 0.5× 296 2.0× 15 860
Andrija Bogdanović Serbia 17 466 1.0× 279 0.9× 141 0.5× 69 0.4× 294 2.0× 96 894
Lisa R. Treviño United States 8 313 0.7× 86 0.3× 259 0.9× 51 0.3× 457 3.2× 15 1.2k

Countries citing papers authored by R E Clark

Since Specialization
Citations

This map shows the geographic impact of R E Clark's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R E Clark with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R E Clark more than expected).

Fields of papers citing papers by R E Clark

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R E Clark. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R E Clark. The network helps show where R E Clark may publish in the future.

Co-authorship network of co-authors of R E Clark

This figure shows the co-authorship network connecting the top 25 collaborators of R E Clark. A scholar is included among the top collaborators of R E Clark based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R E Clark. R E Clark is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Lucas, Claire, R. J. C. Harris, Athina Giannoudis, Elizabeth S. McDonald, & R E Clark. (2014). Low leukotriene B4 receptor 1 leads to ALOX5 downregulation at diagnosis of chronic myeloid leukemia. Haematologica. 99(11). 1710–1715. 13 indexed citations
3.
Snarski, Emilian, John A. Snowden, Maria Carolina Oliveira, et al.. (2014). Onset and outcome of pregnancy after autologous haematopoietic SCT (AHSCT) for autoimmune diseases: a retrospective study of the EBMT autoimmune diseases working party (ADWP). Bone Marrow Transplantation. 50(2). 216–220. 37 indexed citations
4.
Pirmohamed, Munir, et al.. (2011). Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis. Leukemia. 26(3). 490–498. 10 indexed citations
5.
Davies, Andrea, Niove E. Jordanides, Athina Giannoudis, et al.. (2009). Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia. 23(11). 1999–2006. 84 indexed citations
6.
7.
Lucas, Claire, Robert J. Harris, Athina Giannoudis, et al.. (2009). Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 94(10). 1362–1367. 87 indexed citations
8.
Wang, L, Athina Giannoudis, Steven Lane, et al.. (2007). Expression of the Uptake Drug Transporter hOCT1 is an Important Clinical Determinant of the Response to Imatinib in Chronic Myeloid Leukemia. Clinical Pharmacology & Therapeutics. 83(2). 258–264. 207 indexed citations
9.
Clark, R E, Ian D. Kerr, & Richard Callaghan. (2006). Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter. British Journal of Pharmacology. 149(5). 506–515. 87 indexed citations
10.
Clark, R E, et al.. (2001). High frequency of positive surveillance for cytomegalovirus (CMV) by PCR in allograft recipients at low risk of CMV. Bone Marrow Transplantation. 27(6). 615–619. 4 indexed citations
11.
Clark, R E, et al.. (2000). Direct evidence that chronic myeloid leukaemia (CML) cells can express BCR-ABL junctional oligopeptides in association with class IHLA. Nottingham Trent University's Institutional Repository (Nottingham Trent Repository). 1 indexed citations
12.
Clark, R E. (2000). Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems. Leukemia. 14(3). 347–355. 33 indexed citations
13.
Clark, R E, et al.. (1999). Clinical use of streptolysin-O to facilitate antisense oligodeoxyribonucleotide delivery for purging autografts in chronic myeloid leukaemia. Bone Marrow Transplantation. 23(12). 1303–1308. 16 indexed citations
14.
Smith, Andrew, et al.. (1999). Vitamin C, Mood and Cognitive Functioning in the Elderly. Nutritional Neuroscience. 2(4). 249–256. 24 indexed citations
15.
Clark, R E, et al.. (1998). Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplantation. 22(9). 859–863. 49 indexed citations
16.
Franklin, I M, Stephen M. Kelsey, A. C. Newland, et al.. (1997). Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: mobilization of Philadelphia‐negative peripheral blood stem cells. British Journal of Haematology. 96(3). 627–634. 22 indexed citations
17.
Clark, R E, Richard V. Giles, David G. Spiller, & D M Tidd. (1995). EFFECT OF CHIMERIC AND CONVENTIONALLY LINKED ANTISENSE OLIGONUCLEOTIDES ON BCR-ABL EXPRESSION IN INTACT CHRONIC MYELOID-LEUKEMIA CELLS. Experimental Hematology. 23(8). 906–906. 1 indexed citations
18.
Pettitt, Andrew R., et al.. (1994). Vogt-Koyanagi-Harada syndrome complicating allogeneic bone marrow transplantation.. PubMed. 13(2). 225–7. 4 indexed citations
19.
Fahal, Ibrahim H, Peter S. Williams, R E Clark, & G.M. Bell. (1992). Thrombotic thrombocytopenic purpura due to rifampicin.. BMJ. 304(6831). 882–882. 15 indexed citations
20.
Clark, R E, et al.. (1975). Cerebral metastatic choriocarcinoma: a postpartum cause of "stroke".. PubMed. 45(5). 583–8. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gary Vanasse Breakdown of academic impact, for papers by Sven‐Aage Killmann Breakdown of academic impact, for papers by M. Schoester Breakdown of academic impact, for papers by Peter Ernst Breakdown of academic impact, for papers by Tomasz Sacha Breakdown of academic impact, for papers by Marius Dohse Breakdown of academic impact, for papers by M Bouvier Breakdown of academic impact, for papers by Yuri Yanishevski Breakdown of academic impact, for papers by Andrija Bogdanović Breakdown of academic impact, for papers by Lisa R. Treviño
Rankless by CCL
2026